Morning Overview on MSN
An mRNA vaccine paired with Keytruda cut melanoma recurrence by nearly 50% over five years in a landmark NYU-led trial
Patients with high-risk melanoma who received a personalized mRNA cancer vaccine alongside pembrolizumab after surgery saw ...
Morning Overview on MSN
Intismeran autogene plus Keytruda dropped melanoma recurrence by close to 50% over five years in a Moderna-Merck-NYU trial unveiled at ASCO
Patients with high-risk melanoma who received a personalized mRNA cancer vaccine alongside Keytruda saw their risk of disease ...
Merck has rebounded 55% in the past year, driven by optimism around its post-Keytruda strategy despite the looming patent ...
A new mRNA melanoma vaccine from Merck and Moderna showed sustained benefits over five years, cutting the risk of cancer ...
At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran ...
After ICIJ’s The Cancer Calculus investigation exposed a market for falsified Keytruda, two sources confirmed Friday that ...
A study finds that an mRNA vaccine is highly effective at preventing recurrence of this dangerous skin cancer, when used in ...
When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in ...
4don MSN
‘King Keytruda’s reign continues.’ Investors aren’t wowed by a promising new lung cancer drug.
The highly anticipated study found that ivonescimab reduced the risk of death by 34% compared with another drug ...
Merck reported first-quarter results that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. The pharmaceutical giant also narrowed its 2026 sales ...
Moderna and Merck present 5-year data for intismeran autogene in combo with Keytruda in patients with high-risk stage III/IV melanoma following complete resection at 2026 ASCO mee ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results